Press "Enter" to skip to content

New patent expiration for Gilead Sciences drug STRIBILD

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug STRIBILD

Annual Drug Patent Expirations for STRIBILD
Annual Drug Patent Expirations for STRIBILD

Stribild is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for STRIBILD.

This drug has three hundred and eigthy-two patent family members in forty-seven countries.

The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug STRIBILD
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions